Ultime notizie per Goodman Property (OTC:GPPYF) Azioni

Goodman Property Trust is one of New Zealand's property trusts, with a portfolio composed of industrial estates, businesses, and a development bank. After selling its Christchurch assets, Goodman is 100% Auckland-centric. The focus over the next few years will be on selling lower-quality assets and redeploying capital to industrial property in strategically important locations. The investment strategy is premised on management's view that industrial assets in premium locations will generate superior long-term returns from lower average vacancy and higher rent growth.

Goodman Property Trust

News

Guidance

Six Flags Entertainment Says It Is Targeting At Least $800M Of Annual Unlevered Pre-tax Free Cash Flow By 2027

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Buy and maintains $84 price target.

Price Target

Reiteration

Analyst Ratings

CRSP

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $84 Price Target

<a href="https://www.bloomberg.com/news/articles/2024-11-06/kkr-is-said-to-consider-selling-750-million-stake-in-jb-pharma?sref=y3YMCJ4e" title="https://www.bloomberg.com/news/articles/2024-11-06/kkr-is-said-to-consider-selling-750-million-stake-in-jb-pharma?sref=y3YMCJ4e">https://www.bloomberg.com/news/articles/2024-11-06/kkr-is-said-to-consider-selling-750-million-stake-in-jb-pharma?sref=y3YMCJ4e</a>

Asset Sales

Bloomberg Reported KKR Said To Consider Selling $750M Stake In JB Pharma

Toyota Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) reported quarterly sales of $76.29 billion which beat the analyst consensus estimate of $72.27 billion by 5.57 percent.&nbsp;

Earnings

Earnings Beats

Toyota Motor Q2 Sales $76.29B Beat $72.27B Estimate

Cedar Fair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) reported quarterly earnings of $1.10 per share. The company reported quarterly sales of $1.348 billion which beat the analyst consensus estimate of $1.339 billion by 0.67 percent. This is a 60.09 percent increase over sales of $842.009 million the same period last year.

Earnings Misses

Cedar Fair Q3 2024 Adj. EPS $1.10, Sales $1.348B Beat $1.339B Estimate

Morgan Stanley analyst Joseph Moore maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Equal-Weight and lowers the price target from $250 to $235.

NXPI

Morgan Stanley Maintains Equal-Weight on NXP Semiconductors, Lowers Price Target to $235

Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRX#NASDAQ">TCRX</a>) with a Buy and maintains $11 price target.

TCRX

Needham Reiterates Buy on TScan Therapeutics, Maintains $11 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) with a Buy and maintains $32 price target.

IOVA

HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Buy and raises the price target from $80 to $95.

ACLX

HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $95

Deutsche Bank analyst David Begleiter upgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Hold to Buy and lowers the price target from $135 to $110.

Upgrades

Deutsche Bank Upgrades Celanese to Buy, Lowers Price Target to $110

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $7 price target.

KPTI

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

Needham analyst Mike Matson reiterates NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) with a Buy and maintains $19 price target.

Needham Reiterates Buy on NeoGenomics, Maintains $19 Price Target

Needham analyst Gil Blum reiterates Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Buy and maintains $96 price target.

Needham Reiterates Buy on Arcellx, Maintains $96 Price Target

Deutsche Bank analyst Nicole Deblase maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and raises the price target from $136 to $140.

Deutsche Bank Maintains Buy on Emerson Electric, Raises Price Target to $140

KRKR

36kr Holdings Inc. Announced That It Has Recently Teamed Up With Soften Corporation To Launch An Innovative News Hub, The "36kr Market Watch" Wechat Mini Program

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Arcus Biosciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCUS#NYSE">RCUS</a>) with a Neutral and maintains $20 price target.

RCUS

HC Wainwright & Co. Reiterates Neutral on Arcus Biosciences, Maintains $20 Price Target

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are up by over 13% in pre-market trading on Wednesday over a likely Donald Trump victory in the <a href="https://www.benzinga.com/topic/2024-election" target="_blank" rel="noreferrer noopener">U.S. Presidential elections</a>.
What Happened: According <a href="https://www.nytimes.com/live/2024/11/05/us/trump-harris-election" target="_blank" rel="noreferrer noopener">to</a> The New York Times, Trump currently has over 95% chance of victory given he already has <a href="https://www.benzinga.com/news/24/11/41766547/trump-gives-victory-speech-in-florida-as-winning-pennsylvania-puts-him-at-brink-of-victory-vows-to-f" target="_blank" rel="noreferrer noopener">267 of the 270 electoral votes needed to win</a>.
At the time of writing, the Tesla stock was up 13.3% in premarket trading, at $284.90, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Tesla CEO&nbsp;Elon Musk&nbsp;endorsed Trump in July and has been actively campaigning for the former President&nbsp;<a href="https://www.benzinga.com/news/24/11/41709658/stephen-king-slams-elon-musk-claims-most-of-his-posts-spread-pro-trump-disinformation-and-outright-l" target="_blank" rel="noreferrer noopener">both offline and online</a>. Musk even campaigned for Trump in the swing state of Pennsylvania in October.
Trump, meanwhile, has expressed his intent to set up a&nbsp;<a href="https://www.benzinga.com/government/24/09/40739165/trump-plans-to-appoint-elon-musk-to-government-efficiency-commission-if-elected-tesla-ceo-says-hell" target="_blank" rel="noreferrer noopener">government efficiency commission</a>&nbsp;led by Musk if elected President. The commission will be tasked with conducting a complete financial and performance audit of the federal government and recommending reforms, Trump said in September.
According to&nbsp;Wedbush&nbsp;analyst&nbsp;Dan Ives, the&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41766869/trump-win-biggest-positive-for-elon-musks-tesla-tech-bull-says-it-could-boost-ev-gi" target="_blank" rel="noreferrer noopener">biggest positive from a Trump win would be for Tesla and Musk</a>.
"We believe a Trump win is a negative for the EV industry as the EV rebates/tax incentives get pulled, however for Tesla a huge positive for scale/price advantage," Ives said on Wednesday. The analyst added that a Trump win could add $40-$50 to Tesla's stock.
Tesla&#8217;s Frankfurt-listed shares are also up by over 14.5%.
Price Action: Year-to-date, Tesla shares are up 1.2%, after the stock closed up 3.5% at $251.44 on Tuesday, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41738613/elon-musk-rejects-rumors-of-a-tesla-phone-but-says-the-ev-giant-will-have-to-make-one-if-this-happen" target="_blank" rel="noreferrer noopener">Elon Musk Rejects Rumors Of A Tesla Phone, But Says The EV Giant Will Have To Make One If This Happens</a></li>
</ul>
Photo courtesy: Tesla

Equities

WIIM

Pre-Market Outlook

Markets

Tech

TSLA

Tesla Stock Surges Over 13% In Premarket: What Is Going On

Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $85 to $60.

APLS

Needham Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $60

Needham analyst Mayank Tandon maintains Payoneer Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>) with a Buy and raises the price target from $10 to $14.

PAYO

Needham Maintains Buy on Payoneer Global, Raises Price Target to $14

HC Wainwright &amp; Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) with a Buy and maintains $11 price target.

Comments

Goodman Property

Notizie

Ultime notizie per Goodman Property (OTC:GPPYF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO